The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Graft Versus Host Disease Treatment Market Research Report 2024
Synopsis
Market Analysis and Insights: Global Graft Versus Host Disease Treatment Market
The global Graft Versus Host Disease Treatment market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Etanercept accounting for % of the Graft Versus Host Disease Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Acute GVHD segment is altered to an % CAGR throughout this forecast period.
China Graft Versus Host Disease Treatment market size is valued at US$ million in 2021, while the North America and Europe Graft Versus Host Disease Treatment are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Graft Versus Host Disease Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Graft Versus Host Disease Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Graft Versus Host Disease Treatment market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Graft Versus Host Disease Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Graft Versus Host Disease Treatment market.
Global Graft Versus Host Disease Treatment Scope and Market Size
Graft Versus Host Disease Treatment market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Graft Versus Host Disease Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Etanercept
Monoclonal Antibodies
Thalidomide
Tyrosine Kinase Inhibitors
mTOR Inhibitors
Segment by Application
Acute GVHD
Chronic GVHD
Prophylaxis GVHD
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
AbbVie Inc.
Acrofan
Astellas Pharma Inc.
Bristol-Myers Squibb Company
ElsaLys Biotech SA
F. Hoffmann-La Roche AG
Johnson & Johnson
Mallinckrodft PLC
Merck & Co., Inc.
Mesoblast Limited
Neovii Biotech GmbH
Novartis AG
Ocugen, Inc.
Pfizer Inc
Pluristem Therapeutics Inc.
Samedan Ltd
Sanofi SA
Soligenix, Inc.
Market Analysis and Insights: Global Graft Versus Host Disease Treatment Market
The global Graft Versus Host Disease Treatment market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Etanercept accounting for % of the Graft Versus Host Disease Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Acute GVHD segment is altered to an % CAGR throughout this forecast period.
China Graft Versus Host Disease Treatment market size is valued at US$ million in 2021, while the North America and Europe Graft Versus Host Disease Treatment are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Graft Versus Host Disease Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Graft Versus Host Disease Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Graft Versus Host Disease Treatment market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Graft Versus Host Disease Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Graft Versus Host Disease Treatment market.
Global Graft Versus Host Disease Treatment Scope and Market Size
Graft Versus Host Disease Treatment market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Graft Versus Host Disease Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Etanercept
Monoclonal Antibodies
Thalidomide
Tyrosine Kinase Inhibitors
mTOR Inhibitors
Segment by Application
Acute GVHD
Chronic GVHD
Prophylaxis GVHD
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
AbbVie Inc.
Acrofan
Astellas Pharma Inc.
Bristol-Myers Squibb Company
ElsaLys Biotech SA
F. Hoffmann-La Roche AG
Johnson & Johnson
Mallinckrodft PLC
Merck & Co., Inc.
Mesoblast Limited
Neovii Biotech GmbH
Novartis AG
Ocugen, Inc.
Pfizer Inc
Pluristem Therapeutics Inc.
Samedan Ltd
Sanofi SA
Soligenix, Inc.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Graft Versus Host Disease Treatment Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Etanercept
1.2.3 Monoclonal Antibodies
1.2.4 Thalidomide
1.2.5 Tyrosine Kinase Inhibitors
1.2.6 mTOR Inhibitors
1.3 Market by Application
1.3.1 Global Graft Versus Host Disease Treatment Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Acute GVHD
1.3.3 Chronic GVHD
1.3.4 Prophylaxis GVHD
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Graft Versus Host Disease Treatment Market Perspective (2017-2028)
2.2 Graft Versus Host Disease Treatment Growth Trends by Region
2.2.1 Graft Versus Host Disease Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Graft Versus Host Disease Treatment Historic Market Size by Region (2017-2022)
2.2.3 Graft Versus Host Disease Treatment Forecasted Market Size by Region (2023-2028)
2.3 Graft Versus Host Disease Treatment Market Dynamics
2.3.1 Graft Versus Host Disease Treatment Industry Trends
2.3.2 Graft Versus Host Disease Treatment Market Drivers
2.3.3 Graft Versus Host Disease Treatment Market Challenges
2.3.4 Graft Versus Host Disease Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Graft Versus Host Disease Treatment Players by Revenue
3.1.1 Global Top Graft Versus Host Disease Treatment Players by Revenue (2017-2022)
3.1.2 Global Graft Versus Host Disease Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Graft Versus Host Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Graft Versus Host Disease Treatment Revenue
3.4 Global Graft Versus Host Disease Treatment Market Concentration Ratio
3.4.1 Global Graft Versus Host Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Graft Versus Host Disease Treatment Revenue in 2021
3.5 Graft Versus Host Disease Treatment Key Players Head office and Area Served
3.6 Key Players Graft Versus Host Disease Treatment Product Solution and Service
3.7 Date of Enter into Graft Versus Host Disease Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Graft Versus Host Disease Treatment Breakdown Data by Type
4.1 Global Graft Versus Host Disease Treatment Historic Market Size by Type (2017-2022)
4.2 Global Graft Versus Host Disease Treatment Forecasted Market Size by Type (2023-2028)
5 Graft Versus Host Disease Treatment Breakdown Data by Application
5.1 Global Graft Versus Host Disease Treatment Historic Market Size by Application (2017-2022)
5.2 Global Graft Versus Host Disease Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Graft Versus Host Disease Treatment Market Size (2017-2028)
6.2 North America Graft Versus Host Disease Treatment Market Size by Country (2017-2022)
6.3 North America Graft Versus Host Disease Treatment Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Graft Versus Host Disease Treatment Market Size (2017-2028)
7.2 Europe Graft Versus Host Disease Treatment Market Size by Country (2017-2022)
7.3 Europe Graft Versus Host Disease Treatment Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Graft Versus Host Disease Treatment Market Size (2017-2028)
8.2 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Country (2017-2022)
8.3 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Graft Versus Host Disease Treatment Market Size (2017-2028)
9.2 Latin America Graft Versus Host Disease Treatment Market Size by Country (2017-2022)
9.3 Latin America Graft Versus Host Disease Treatment Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Graft Versus Host Disease Treatment Market Size (2017-2028)
10.2 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Country (2017-2022)
10.3 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Company Detail
11.1.2 AbbVie Inc. Business Overview
11.1.3 AbbVie Inc. Graft Versus Host Disease Treatment Introduction
11.1.4 AbbVie Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.1.5 AbbVie Inc. Recent Development
11.2 Acrofan
11.2.1 Acrofan Company Detail
11.2.2 Acrofan Business Overview
11.2.3 Acrofan Graft Versus Host Disease Treatment Introduction
11.2.4 Acrofan Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.2.5 Acrofan Recent Development
11.3 Astellas Pharma Inc.
11.3.1 Astellas Pharma Inc. Company Detail
11.3.2 Astellas Pharma Inc. Business Overview
11.3.3 Astellas Pharma Inc. Graft Versus Host Disease Treatment Introduction
11.3.4 Astellas Pharma Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.3.5 Astellas Pharma Inc. Recent Development
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Company Detail
11.4.2 Bristol-Myers Squibb Company Business Overview
11.4.3 Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Introduction
11.4.4 Bristol-Myers Squibb Company Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.4.5 Bristol-Myers Squibb Company Recent Development
11.5 ElsaLys Biotech SA
11.5.1 ElsaLys Biotech SA Company Detail
11.5.2 ElsaLys Biotech SA Business Overview
11.5.3 ElsaLys Biotech SA Graft Versus Host Disease Treatment Introduction
11.5.4 ElsaLys Biotech SA Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.5.5 ElsaLys Biotech SA Recent Development
11.6 F. Hoffmann-La Roche AG
11.6.1 F. Hoffmann-La Roche AG Company Detail
11.6.2 F. Hoffmann-La Roche AG Business Overview
11.6.3 F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Introduction
11.6.4 F. Hoffmann-La Roche AG Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.6.5 F. Hoffmann-La Roche AG Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Detail
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Graft Versus Host Disease Treatment Introduction
11.7.4 Johnson & Johnson Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.7.5 Johnson & Johnson Recent Development
11.8 Mallinckrodft PLC
11.8.1 Mallinckrodft PLC Company Detail
11.8.2 Mallinckrodft PLC Business Overview
11.8.3 Mallinckrodft PLC Graft Versus Host Disease Treatment Introduction
11.8.4 Mallinckrodft PLC Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.8.5 Mallinckrodft PLC Recent Development
11.9 Merck & Co., Inc.
11.9.1 Merck & Co., Inc. Company Detail
11.9.2 Merck & Co., Inc. Business Overview
11.9.3 Merck & Co., Inc. Graft Versus Host Disease Treatment Introduction
11.9.4 Merck & Co., Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.9.5 Merck & Co., Inc. Recent Development
11.10 Mesoblast Limited
11.10.1 Mesoblast Limited Company Detail
11.10.2 Mesoblast Limited Business Overview
11.10.3 Mesoblast Limited Graft Versus Host Disease Treatment Introduction
11.10.4 Mesoblast Limited Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.10.5 Mesoblast Limited Recent Development
11.11 Neovii Biotech GmbH
11.11.1 Neovii Biotech GmbH Company Detail
11.11.2 Neovii Biotech GmbH Business Overview
11.11.3 Neovii Biotech GmbH Graft Versus Host Disease Treatment Introduction
11.11.4 Neovii Biotech GmbH Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.11.5 Neovii Biotech GmbH Recent Development
11.12 Novartis AG
11.12.1 Novartis AG Company Detail
11.12.2 Novartis AG Business Overview
11.12.3 Novartis AG Graft Versus Host Disease Treatment Introduction
11.12.4 Novartis AG Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.12.5 Novartis AG Recent Development
11.13 Ocugen, Inc.
11.13.1 Ocugen, Inc. Company Detail
11.13.2 Ocugen, Inc. Business Overview
11.13.3 Ocugen, Inc. Graft Versus Host Disease Treatment Introduction
11.13.4 Ocugen, Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.13.5 Ocugen, Inc. Recent Development
11.14 Pfizer Inc
11.14.1 Pfizer Inc Company Detail
11.14.2 Pfizer Inc Business Overview
11.14.3 Pfizer Inc Graft Versus Host Disease Treatment Introduction
11.14.4 Pfizer Inc Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.14.5 Pfizer Inc Recent Development
11.15 Pluristem Therapeutics Inc.
11.15.1 Pluristem Therapeutics Inc. Company Detail
11.15.2 Pluristem Therapeutics Inc. Business Overview
11.15.3 Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Introduction
11.15.4 Pluristem Therapeutics Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.15.5 Pluristem Therapeutics Inc. Recent Development
11.16 Samedan Ltd
11.16.1 Samedan Ltd Company Detail
11.16.2 Samedan Ltd Business Overview
11.16.3 Samedan Ltd Graft Versus Host Disease Treatment Introduction
11.16.4 Samedan Ltd Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.16.5 Samedan Ltd Recent Development
11.17 Sanofi SA
11.17.1 Sanofi SA Company Detail
11.17.2 Sanofi SA Business Overview
11.17.3 Sanofi SA Graft Versus Host Disease Treatment Introduction
11.17.4 Sanofi SA Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.17.5 Sanofi SA Recent Development
11.18 Soligenix, Inc.
11.18.1 Soligenix, Inc. Company Detail
11.18.2 Soligenix, Inc. Business Overview
11.18.3 Soligenix, Inc. Graft Versus Host Disease Treatment Introduction
11.18.4 Soligenix, Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.18.5 Soligenix, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Graft Versus Host Disease Treatment Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Etanercept
Table 3. Key Players of Monoclonal Antibodies
Table 4. Key Players of Thalidomide
Table 5. Key Players of Tyrosine Kinase Inhibitors
Table 6. Key Players of mTOR Inhibitors
Table 7. Global Graft Versus Host Disease Treatment Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global Graft Versus Host Disease Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Graft Versus Host Disease Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 10. Global Graft Versus Host Disease Treatment Market Share by Region (2017-2022)
Table 11. Global Graft Versus Host Disease Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 12. Global Graft Versus Host Disease Treatment Market Share by Region (2023-2028)
Table 13. Graft Versus Host Disease Treatment Market Trends
Table 14. Graft Versus Host Disease Treatment Market Drivers
Table 15. Graft Versus Host Disease Treatment Market Challenges
Table 16. Graft Versus Host Disease Treatment Market Restraints
Table 17. Global Graft Versus Host Disease Treatment Revenue by Players (2017-2022) & (US$ Million)
Table 18. Global Graft Versus Host Disease Treatment Market Share by Players (2017-2022)
Table 19. Global Top Graft Versus Host Disease Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Graft Versus Host Disease Treatment as of 2021)
Table 20. Ranking of Global Top Graft Versus Host Disease Treatment Companies by Revenue (US$ Million) in 2021
Table 21. Global 5 Largest Players Market Share by Graft Versus Host Disease Treatment Revenue (CR5 and HHI) & (2017-2022)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Graft Versus Host Disease Treatment Product Solution and Service
Table 24. Date of Enter into Graft Versus Host Disease Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Graft Versus Host Disease Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 27. Global Graft Versus Host Disease Treatment Revenue Market Share by Type (2017-2022)
Table 28. Global Graft Versus Host Disease Treatment Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 29. Global Graft Versus Host Disease Treatment Revenue Market Share by Type (2023-2028)
Table 30. Global Graft Versus Host Disease Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 31. Global Graft Versus Host Disease Treatment Revenue Market Share by Application (2017-2022)
Table 32. Global Graft Versus Host Disease Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 33. Global Graft Versus Host Disease Treatment Revenue Market Share by Application (2023-2028)
Table 34. North America Graft Versus Host Disease Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 35. North America Graft Versus Host Disease Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 36. Europe Graft Versus Host Disease Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 37. Europe Graft Versus Host Disease Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 38. Asia-Pacific Graft Versus Host Disease Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 39. Asia-Pacific Graft Versus Host Disease Treatment Market Size by Region (2023-2028) & (US$ Million)
Table 40. Latin America Graft Versus Host Disease Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 41. Latin America Graft Versus Host Disease Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 42. Middle East & Africa Graft Versus Host Disease Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 43. Middle East & Africa Graft Versus Host Disease Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 44. AbbVie Inc. Company Detail
Table 45. AbbVie Inc. Business Overview
Table 46. AbbVie Inc. Graft Versus Host Disease Treatment Product
Table 47. AbbVie Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 48. AbbVie Inc. Recent Development
Table 49. Acrofan Company Detail
Table 50. Acrofan Business Overview
Table 51. Acrofan Graft Versus Host Disease Treatment Product
Table 52. Acrofan Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 53. Acrofan Recent Development
Table 54. Astellas Pharma Inc. Company Detail
Table 55. Astellas Pharma Inc. Business Overview
Table 56. Astellas Pharma Inc. Graft Versus Host Disease Treatment Product
Table 57. Astellas Pharma Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 58. Astellas Pharma Inc. Recent Development
Table 59. Bristol-Myers Squibb Company Company Detail
Table 60. Bristol-Myers Squibb Company Business Overview
Table 61. Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Product
Table 62. Bristol-Myers Squibb Company Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 63. Bristol-Myers Squibb Company Recent Development
Table 64. ElsaLys Biotech SA Company Detail
Table 65. ElsaLys Biotech SA Business Overview
Table 66. ElsaLys Biotech SA Graft Versus Host Disease Treatment Product
Table 67. ElsaLys Biotech SA Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 68. ElsaLys Biotech SA Recent Development
Table 69. F. Hoffmann-La Roche AG Company Detail
Table 70. F. Hoffmann-La Roche AG Business Overview
Table 71. F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Product
Table 72. F. Hoffmann-La Roche AG Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 73. F. Hoffmann-La Roche AG Recent Development
Table 74. Johnson & Johnson Company Detail
Table 75. Johnson & Johnson Business Overview
Table 76. Johnson & Johnson Graft Versus Host Disease Treatment Product
Table 77. Johnson & Johnson Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 78. Johnson & Johnson Recent Development
Table 79. Mallinckrodft PLC Company Detail
Table 80. Mallinckrodft PLC Business Overview
Table 81. Mallinckrodft PLC Graft Versus Host Disease Treatment Product
Table 82. Mallinckrodft PLC Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 83. Mallinckrodft PLC Recent Development
Table 84. Merck & Co., Inc. Company Detail
Table 85. Merck & Co., Inc. Business Overview
Table 86. Merck & Co., Inc. Graft Versus Host Disease Treatment Product
Table 87. Merck & Co., Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 88. Merck & Co., Inc. Recent Development
Table 89. Mesoblast Limited Company Detail
Table 90. Mesoblast Limited Business Overview
Table 91. Mesoblast Limited Graft Versus Host Disease Treatment Product
Table 92. Mesoblast Limited Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 93. Mesoblast Limited Recent Development
Table 94. Neovii Biotech GmbH Company Detail
Table 95. Neovii Biotech GmbH Business Overview
Table 96. Neovii Biotech GmbH Graft Versus Host Disease TreatmentProduct
Table 97. Neovii Biotech GmbH Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 98. Neovii Biotech GmbH Recent Development
Table 99. Novartis AG Company Detail
Table 100. Novartis AG Business Overview
Table 101. Novartis AG Graft Versus Host Disease TreatmentProduct
Table 102. Novartis AG Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 103. Novartis AG Recent Development
Table 104. Ocugen, Inc. Company Detail
Table 105. Ocugen, Inc. Business Overview
Table 106. Ocugen, Inc. Graft Versus Host Disease TreatmentProduct
Table 107. Ocugen, Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 108. Ocugen, Inc. Recent Development
Table 109. Pfizer Inc Company Detail
Table 110. Pfizer Inc Business Overview
Table 111. Pfizer Inc Graft Versus Host Disease TreatmentProduct
Table 112. Pfizer Inc Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 113. Pfizer Inc Recent Development
Table 114. Pluristem Therapeutics Inc. Company Detail
Table 115. Pluristem Therapeutics Inc. Business Overview
Table 116. Pluristem Therapeutics Inc. Graft Versus Host Disease TreatmentProduct
Table 117. Pluristem Therapeutics Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 118. Pluristem Therapeutics Inc. Recent Development
Table 119. Samedan Ltd Company Detail
Table 120. Samedan Ltd Business Overview
Table 121. Samedan Ltd Graft Versus Host Disease TreatmentProduct
Table 122. Samedan Ltd Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 123. Samedan Ltd Recent Development
Table 124. Sanofi SA Company Detail
Table 125. Sanofi SA Business Overview
Table 126. Sanofi SA Graft Versus Host Disease TreatmentProduct
Table 127. Sanofi SA Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 128. Sanofi SA Recent Development
Table 129. Soligenix, Inc. Company Detail
Table 130. Soligenix, Inc. Business Overview
Table 131. Soligenix, Inc. Graft Versus Host Disease TreatmentProduct
Table 132. Soligenix, Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 133. Soligenix, Inc. Recent Development
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Graft Versus Host Disease Treatment Market Share by Type: 2021 VS 2028
Figure 2. Etanercept Features
Figure 3. Monoclonal Antibodies Features
Figure 4. Thalidomide Features
Figure 5. Tyrosine Kinase Inhibitors Features
Figure 6. mTOR Inhibitors Features
Figure 7. Global Graft Versus Host Disease Treatment Market Share by Application in 2021 & 2028
Figure 8. Acute GVHD Case Studies
Figure 9. Chronic GVHD Case Studies
Figure 10. Prophylaxis GVHD Case Studies
Figure 11. Graft Versus Host Disease Treatment Report Years Considered
Figure 12. Global Graft Versus Host Disease Treatment Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 13. Global Graft Versus Host Disease Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Graft Versus Host Disease Treatment Market Share by Region: 2021 VS 2028
Figure 15. Global Graft Versus Host Disease Treatment Market Share by Players in 2021
Figure 16. Global Top Graft Versus Host Disease Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Graft Versus Host Disease Treatment as of 2021)
Figure 17. The Top 10 and 5 Players Market Share by Graft Versus Host Disease Treatment Revenue in 2021
Figure 18. North America Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. North America Graft Versus Host Disease Treatment Market Share by Country (2017-2028)
Figure 20. United States Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Canada Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Europe Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Europe Graft Versus Host Disease Treatment Market Share by Country (2017-2028)
Figure 24. Germany Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. France Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. U.K. Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Italy Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Russia Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Nordic Countries Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Asia-Pacific Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Asia-Pacific Graft Versus Host Disease Treatment Market Share by Region (2017-2028)
Figure 32. China Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Japan Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. South Korea Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Southeast Asia Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. India Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Australia Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Latin America Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Latin America Graft Versus Host Disease Treatment Market Share by Country (2017-2028)
Figure 40. Mexico Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Brazil Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Middle East & Africa Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Middle East & Africa Graft Versus Host Disease Treatment Market Share by Country (2017-2028)
Figure 44. Turkey Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Saudi Arabia Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. AbbVie Inc. Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 47. Acrofan Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 48. Astellas Pharma Inc. Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 49. Bristol-Myers Squibb Company Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 50. ElsaLys Biotech SA Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 51. F. Hoffmann-La Roche AG Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 52. Johnson & Johnson Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 53. Mallinckrodft PLC Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 54. Merck & Co., Inc. Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 55. Mesoblast Limited Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 56. Neovii Biotech GmbH Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 57. Novartis AG Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 58. Ocugen, Inc. Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 59. Pfizer Inc Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 60. Pluristem Therapeutics Inc. Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 61. Samedan Ltd Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 62. Sanofi SA Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 63. Soligenix, Inc. Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
